Ab

Abbisko

Shanghai CNFounded 2016100 employees
Private CapbiotechPrivateOncology
Platform: ALK/ROS1
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
3
FDA Approved
0
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
NiratapinarofABB-9621Phase 2/31VaccineB7-H3IL-23iUrothelial CaSCD
PolafotisoranABB-5920Phase 2/32NanobodyPLK4PD-L1iALLLGS
ABB-879ABB-879Phase 11Gene EditingWEE1VEGFiMigraineALS
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (3)
2025-07-08
Niratapinarof Ph3 Readout
Urothelial Ca
Past
2029-10-07
ABB-879 Interim
ALS
Interim
2030-07-23
Polafotisoran Ph3 Readout
ALL
Ph3 Readout